On May 1, 2017, the Federal Circuit published its decision in Helsinn Healthcare v. Teva Pharmaceuticals, No. 3:11-cv-03962-MLC-DEA, (May. 1, 2017) concerning infringement of four patents: U.S. Patent Nos. 7,947,724 ("'724 patent"); 7,947,725 ("'725 patent"); 7,960,424 ("'424 patent") and 8,598,219 ("'219 patent"). Teva defended that the patents were invalid under the "on-sale bar" provision of 35 USC §102. The District Court held that Teva infringed all of the patents and that the patents were not invalid. Teva appealed. The Federal Circuit reversed the District Court's decision, holding that all four patents were invalid and thus not infringed.
On Wednesday, March 8, 2017, the Federal Circuit published its decision in Thales Visionix Inc. v. United States, No. 1:14-cv-00513-TCW, (Mar. 8, 2017) concerning infringement of U.S. Patent No. 6,474,159. Thales Visionix appealed from the US Court of Federal Claims judgment holding that the claims were directed to patent-ineligible subject matter. The Federal Circuit reversed the Claims Court's decision and remanded for further proceedings.
On Wednesday, February 22, 2017, the Supreme Court published its decision in Life Technologies Corp. v. Promega Corp. 580 U.S. __ (2017), concerning infringement of US Patent RE 37,984. The question before the Court was whether supplying a single component of a multicomponent invention overseas constitutes an infringing act under 35 U. S. C. §271(f)(1).